Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients

Pharmacogenomics

Volumn 8, Issue 4, 2007, Pages 329-337

  Cho, Hyun Jung ^a   Sohn, Kie Ho ^b   Park, Hyang Mi ^b   Lee, Kyung Hoon ^a   Choi, Bo Young ^b   Kim, Seonwoo ^b   Kim, June Soo ^a   On, Young Keun ^a   Chun, Mi Ryung ^a   Kim, Hee Jin ^a   Kim, Jong Won ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

CYP2C9; Korean; VKORC1; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYTOCHROME P450 2C9; DIURETIC AGENT; GENOMIC DNA; MENADIONE EPOXIDE; MENADIONE EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; ORAL ANTIDIABETIC AGENT; PROPAFENONE; SIMVASTATIN; STEROID; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; THROMBOSIS; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; VARIATION (GENETICS); WARFARIN;

EID: 34247109142     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.4.329     Document Type: Article

References (37)

1. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70, 159-164 (2001).
2. Takahashi H, Wilkinson GR, Caraco Y et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263 (2003).
3. Zhao F, Loke C, Rankin SC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76, 210-219 (2004).
4. Yu HC, Chan TY, Critchley JA, Woo KS: Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89, 127-135 (1996).
5. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14, 539-547 (2004).
6. Kamali F, Khan TI, King BP et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75, 204-212 (2004).
7. Franco V, Polanczyk CA, Clausell N, Rohde LE: Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am. J. Med. 116, 651-656 (2004).
8. Blann A, Hewitt J, Siddiqui F, Bareford D: Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br. J. Haematol. 107, 207-209 (1999).
9. Absher RK, Moore ME, Parker MH: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36, 1512-1517 (2002).
10. Gan GG, Teh A, Goh KY, Chong HT, Pang KW: Racial background is a determinant factor in the maintenance dosage of warfarin. Int. J. Hematol. 78, 84-86 (2003).
11. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
12. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
13. O'Reilly RA: Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther. 16, 348-354 (1974).
14. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
15. Furuya H, Fernandez-Salguero P, Gregory W et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392 (1995).
16. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
17. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
18. Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).
19. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug. Deliv. Rev. 54, 1257-1270 (2002).
20. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
21. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
22. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD: Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb. Haemost. 93, 23-26 (2005).
23. Bodin L, Verstuyft C, Tregouet DA et al.: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
24. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
25. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
26. Mushiroda T, Ohnishi Y, Saito S et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51, 249-253 (2006).
27. Obayashi K, Nakamura K, Kawana J et al.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (2006).
28. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
29. Veenstra DL, You JHS, Rieder MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
30. Sconce EA, Khan TI, Wynne WP et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
31. Than LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
32. Larramendy-Gozalo C, Yang JQ, Verstuyft C et al.: Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin. Pharmacol. Toxicol. 98, 611-613 (2006).
33. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
34. Bae JW, Kim HK, Kim JH et al.: Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60, 418-422 (2005).
35. Wang SL, Huang J, Lai MD et al.: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42 (1995).
36. Kimura M, Ieiri I, Mamiya K et al.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20, 243-247 (1998).
37. Imai J, Ieiri I, Mamiya K et al.: Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10, 85-89 (2000).